Polydeoxyribonucleotide (PDRN) promotes human osteoblast proliferation: a new proposal for bone tissue repair.
Several researchers have recently shed new light upon the importance of extracellular nucleotides and nucleosides to stimulate cells growth. PDRN, a mixture of deoxyribonucleotides polymers of different lengths, has recently demonstrated to stimulate "in vitro" fibroblast proliferation and collagen production, probably stimulating the purinergic receptor system. In this work we evaluated the effects of PDRN on human cultured osteoblasts, focusing our attention on cell proliferation and alkaline phosphatase activity. PDRN at a concentration of 100 microg/ml induce an increase in osteoblasts growth after 6 days as compared to control (+21%). The addition of DMPX 50 microM and suramine (P2 inhibitor) 10 microM give different results: suramine has no significant effect, while DPMX reduce, even if partially, the PDRN induced cell growth. The alkaline phosphatase activity shows a gradual enhancement starting from day 0 to day 10, even if PDRN treated cells, examined at day 6, present a sensibly lower phosphatase activity when compared to controls. Our data demonstrate that PDRN acts as an osteoblast growth stimulator. Its action is partially due to a stimulation of the purinergic system mediated by A2 purinoreceptors, however we can not exclude the involvement of other mechanism like salvage pathway.
Guizzardi
Stefano
S
Department of Experimental Medicine--Section of Histology, Via Volturno 39, University of Parma, 43100 Parma, Italy. stegui@unipr.it
Galli
Carlo
C
Govoni
Paolo
P
Boratto
Renata
R
Cattarini
Giulia
G
Martini
Desiree
D
Belletti
Silvana
S
Scandroglio
Renato
R
D000469:Alkaline Phosphatase / Q000378:metabolism; D001861:Bone Regeneration / Q000502:physiology*; D002455:Cell Division / Q000187:drug effects; D002478:Cells, Cultured; D002675:Child, Preschool; D006801:Humans; D010006:Osteoblasts / Q000187:drug effects* / Q000201:enzymology; D011089:Polydeoxyribonucleotides / Q000494:pharmacology*; D058915:Purinergic P1 Receptor Antagonists; D058919:Purinergic P2 Receptor Antagonists; D013498:Suramin / Q000494:pharmacology; D013805:Theobromine / Q000031:analogs & derivatives* / Q000494:pharmacology
D011089:Polydeoxyribonucleotides; D058915:Purinergic P1 Receptor Antagonists; D058919:Purinergic P2 Receptor Antagonists; C057837:3,7-dimethyl-1-propargylxanthine; D013498:Suramin; D000469:Alkaline Phosphatase; D013805:Theobromine